Llwytho...
Dabrafenib and trametinib in BRAFV600E mutated glioma
BRAFV600E mutations have been identified in a number of glioma subtypes, most frequently in pleomorphic xanthoastrocytoma, ganglioglioma, pilocytic astrocytoma, and epithelioid glioblastoma. Although the development of BRAF inhibitors has dramatically improved the clinical outcome for patients with...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | CNS Oncol |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Future Medicine Ltd
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6004887/ https://ncbi.nlm.nih.gov/pubmed/28984141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns-2017-0006 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|